Abstract
Despite being the sixth most common cancer type worldwide, head and neck squamous cell carcinoma (HNSCC) exhibits low five-year survival rates for advanced-stage patients. The local control probability after radiotherapy crucially depends on efficient depletion of the pluripotent sub-population of tumor cells. These cancer stem cells (CSCs) are characterized by an active DNA repair and, consequently, an enhanced radio(chemo)therapy resistance. This study provides evidence that due to its involvement in the regulation of the DNA damage response and stem cell phenotype, the CSC-related transcription factor Oct4 contributes to HNSCC radioresistance. In a siRNA-mediated Oct4 knockdown model, we observed reduced self-renewal capacity and partial radiosensitization of HNSCC cell lines accompanied by decreased expression of the cell cycle checkpoint kinases Chk-1 and WEE1. Consequently, Oct4 knockdown impaired the G2 checkpoint induction after irradiation, linking Oct4 to the HNSCC DNA damage response. Upon CRISPR/Cas9-mediated knockout of the pluripotency-related isoform Oct4 A, radiosensitization of HNSCC cells could only be achieved in combination treatment with the PARP inhibitor Olaparib. In addition, irradiation-induced up-regulation of DNA repair genes, such as the homologous recombination repair (HRR) gene BRCA1, was abolished in Oct4 A knockout cells, indicating that Oct4 A depletion leads to HRR deficiency in HNSCC cells. Further analysis of the Oct4-correlating gene signature in the HNSCC TCGA patient dataset identified the HRR genes PSMC3IP and RAD54L showing a significant correlation with the overall survival of radiotherapy-treated HNSCC patients. The HNSCC self-renewal capacity and clonogenic cell survival after irradiation was reduced upon siRNA-mediated PSMC3IP and RAD54L knockdown, emphasizing the interplay between DNA repair and the CSC phenotype in HNSCC radioresistance mechanisms. All in all, the involvement of Oct4 in the regulation of DNA repair and cell cycle progression provides new insights into HNSCC radioresistance and opens possibilities for combination therapy with PARP inhibitors.
Supplementary Materials
The following are available online at https://www.mdpi.com/article/10.3390/IECC2021-09224/s1.
Institutional Review Board Statement
Ethical approval for this retrospective analysis of clinical and biological data was obtained from the local Ethics Committee.
Informed Consent Statement
Written informed consent was obtained from all patients.
Data Availability Statement
All data supporting the findings of this study are available from the corresponding authors upon request. Gene expression data generated during the study available in the public repository Gene Expression Omnibus (GEO), accession no GSE173161.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).